Search

Displaying results 4321 - 4330 of 6076 in total
  1. Drug

    Levonadifloxacin

    go.drugbank.com/drugs/DB16219
    Investigational

    Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)).

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Flomoxef

    go.drugbank.com/drugs/DB11935
    Investigational

    Flomoxef has been used in trials studying the treatment of Urinary Tract Infection.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Furazidin

    go.drugbank.com/drugs/DB13475
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Betamipron

    go.drugbank.com/drugs/DB19858
    Experimental

    Betamipron is a small molecule drug. Betamipron has a monoisotopic molecular weight of 193.07 Da.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    HNM01

    go.drugbank.com/drugs/DB06531
    Experimental

    It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase

  6. Drug

    VPM4001

    go.drugbank.com/drugs/DB05089
    Experimental

    VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma.

  7. Drug

    Sonepcizumab

    go.drugbank.com/drugs/DB06305
    Investigational

    S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1).

  8. Drug

    Dipotassium phosphate

    go.drugbank.com/drugs/DB09414
    ApprovedInvestigational

    Dipotassium phosphate (K2HPO4) is a highly water-soluble salt often used as a fertilizer and food additive as a source of phosphorus and potassium as well as a buffering agent.

    Mixtures: Instillation Medium for Immucyst
  9. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    GFT14 is a new class of medicaction for treatment of cardiometabolic disease. … Orally absorbed GFT14 has absolutely no structural link with current treatments for dyslipidemia (statin or fibrate based).

  10. Drug

    IDM-2

    go.drugbank.com/drugs/DB05293
    Experimental

    IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.